Learn More
Description
The 55R-286 antibody reacts with the extracellular region of the 55 kDa receptor for the mouse cytokines, Tumor Necrosis Factor (TNF) and lymphotoxin- α (LT- α). This receptor, referred to as the p55 or Type I Tumor Necrosis Factor Receptor (TNFRI) [aka, CD120a], is expressed by a variety of cell lines and normal cell types including T cells, monocytes, macrophages, and neutrophils. B cells express very low or undetectable levels of TNFRI whereas mature erythrocytes are uniformly negative for TNFRI expression. In addition, the 55R-286 antibody can bind to a soluble, truncated form of the mouse Type I TNFR that is shed by cells in response to certain stimuli, e.g., cells treated with LPS or TNF. The in vivo administration of nonblocking, nonagonistic 55R-286 antibody reportedly results in the linear accumulation of shed, soluble forms of the TNFRI in the circulation. The 55R-286 antibody does not recognize the 75 kD (p75) Type II TNFR (aka, CD120b). 55R-286 does not block the binding and does not neutralize the bioactivity of the TNF ligand on L929 target cell populations that express TNFRI. The immunogen used to generate the 55R-286 hybridoma was a purified, soluble extracellular domain of the mouse TNFRI.
Specifications
Specifications
| Antigen | CD120a |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | 55R-286 |
| Concentration | 0.5mg/mL |
| Conjugate | Unconjugated |
| Description | TNF Receptor, Type I/p55 |
| Formulation | Aqueous buffered solution containing ≤0.09% sodium azide. |
| Host Species | Hamster |
| Immunogen | Mouse TNFRI |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.